Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 20, 2007

Baxter to Invest $44M to Develop PEGylated Hemophilia Treatments with Nektar

  • Nektar Therapeutics reports an agreement with subsidiaries of Baxter International to develop new PEGylated therapeutics for hemophilia. The program is expected to begin preclinical development in 2008.

    Nektar will receive up to $44 million in upfront and milestone payments, funding of R&D, and manufacturing revenues during research, clinical development, and commercialization. Nektar will also receive royalties on end product sales.

    Baxter will be responsible for the development and commercialization of the product. Nektar will handle the technology development used in the product including the provision of clinical and commercial PEG reagents.

    This is the second collaboration between Nektar and Baxter related to hemophilia. The two companies inked their initial agreement in September of 2005 to develop PEGylated therapeutic forms of clotting proteins to treat hemophilia A.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »